
<div id="jpedal" style="overflow: hidden; position: relative; width: 909px; height: 1212px;">
<style type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position:absolute;
	white-space:nowrap;
	overflow:visible;
}
</style>
<style type="text/css" >

#t1_2{left:55px;top:86px;word-spacing:4.6px;}
#t2_2{left:55px;top:104px;word-spacing:12.6px;}
#t3_2{left:55px;top:118px;word-spacing:14.7px;}
#t4_2{left:55px;top:132px;word-spacing:10.2px;}
#t5_2{left:55px;top:145px;word-spacing:5.8px;}
#t6_2{left:55px;top:159px;word-spacing:2.4px;}
#t7_2{left:55px;top:173px;word-spacing:2.9px;}
#t8_2{left:55px;top:186px;word-spacing:20.8px;}
#t9_2{left:55px;top:200px;word-spacing:6.5px;}
#ta_2{left:55px;top:214px;word-spacing:4.3px;}
#tb_2{left:55px;top:228px;word-spacing:12.9px;}
#tc_2{left:55px;top:241px;word-spacing:3.8px;}
#td_2{left:196px;top:241px;}
#te_2{left:208px;top:241px;word-spacing:-4.3px;}
#tf_2{left:255px;top:240px;}
#tg_2{left:264px;top:240px;}
#th_2{left:269px;top:241px;word-spacing:3.8px;}
#ti_2{left:55px;top:255px;word-spacing:18.3px;}
#tj_2{left:55px;top:269px;word-spacing:10.8px;}
#tk_2{left:55px;top:282px;word-spacing:5.8px;}
#tl_2{left:55px;top:296px;word-spacing:6.2px;}
#tm_2{left:55px;top:310px;word-spacing:0.6px;}
#tn_2{left:55px;top:323px;word-spacing:7.3px;}
#to_2{left:55px;top:337px;word-spacing:3.5px;}
#tp_2{left:178px;top:336px;}
#tq_2{left:67px;top:351px;word-spacing:16.4px;}
#tr_2{left:55px;top:365px;word-spacing:7.1px;}
#ts_2{left:55px;top:378px;word-spacing:15.5px;}
#tt_2{left:55px;top:392px;word-spacing:5.5px;}
#tu_2{left:55px;top:406px;word-spacing:1.9px;}
#tv_2{left:55px;top:419px;word-spacing:2.7px;}
#tw_2{left:55px;top:433px;word-spacing:5.7px;}
#tx_2{left:55px;top:447px;word-spacing:7.8px;}
#ty_2{left:55px;top:460px;word-spacing:0.1px;}
#tz_2{left:55px;top:474px;word-spacing:14.1px;}
#t10_2{left:55px;top:488px;word-spacing:4.5px;}
#t11_2{left:55px;top:502px;word-spacing:9.4px;}
#t12_2{left:55px;top:515px;word-spacing:2.5px;}
#t13_2{left:55px;top:529px;word-spacing:-0.3px;}
#t14_2{left:55px;top:543px;word-spacing:3.9px;}
#t15_2{left:67px;top:556px;word-spacing:6.6px;}
#t16_2{left:55px;top:570px;word-spacing:6.8px;}
#t17_2{left:55px;top:584px;word-spacing:9.8px;}
#t18_2{left:55px;top:597px;word-spacing:6.6px;}
#t19_2{left:243px;top:597px;}
#t1a_2{left:249px;top:597px;}
#t1b_2{left:280px;top:597px;}
#t1c_2{left:292px;top:597px;word-spacing:6.5px;}
#t1d_2{left:55px;top:611px;}
#t1e_2{left:55px;top:661px;}
#t1f_2{left:55px;top:680px;word-spacing:2.8px;}
#t1g_2{left:55px;top:695px;word-spacing:9.9px;}
#t1h_2{left:55px;top:710px;word-spacing:0.7px;}
#t1i_2{left:55px;top:725px;word-spacing:1.4px;}
#t1j_2{left:55px;top:741px;word-spacing:3.4px;}
#t1k_2{left:55px;top:756px;word-spacing:11.7px;}
#t1l_2{left:55px;top:771px;word-spacing:5px;}
#t1m_2{left:55px;top:786px;word-spacing:8.7px;}
#t1n_2{left:55px;top:801px;word-spacing:2.5px;}
#t1o_2{left:55px;top:817px;word-spacing:16.7px;}
#t1p_2{left:55px;top:832px;word-spacing:5.4px;}
#t1q_2{left:55px;top:847px;word-spacing:19.5px;}
#t1r_2{left:55px;top:862px;word-spacing:5.2px;}
#t1s_2{left:55px;top:877px;word-spacing:4px;}
#t1t_2{left:199px;top:876px;}
#t1u_2{left:208px;top:876px;}
#t1v_2{left:219px;top:877px;word-spacing:8.3px;}
#t1w_2{left:273px;top:877px;}
#t1x_2{left:286px;top:877px;}
#t1y_2{left:295px;top:877px;}
#t1z_2{left:308px;top:877px;word-spacing:8.2px;}
#t20_2{left:332px;top:877px;}
#t21_2{left:345px;top:877px;}
#t22_2{left:355px;top:877px;}
#t23_2{left:367px;top:877px;word-spacing:8.2px;}
#t24_2{left:392px;top:877px;}
#t25_2{left:405px;top:877px;}
#t26_2{left:414px;top:877px;}
#t27_2{left:427px;top:877px;}
#t28_2{left:55px;top:893px;word-spacing:0.9px;}
#t29_2{left:90px;top:893px;}
#t2a_2{left:102px;top:893px;}
#t2b_2{left:112px;top:893px;}
#t2c_2{left:125px;top:893px;word-spacing:1px;}
#t2d_2{left:55px;top:908px;word-spacing:0.2px;}
#t2e_2{left:55px;top:923px;word-spacing:4.6px;}
#t2f_2{left:69px;top:938px;word-spacing:19.5px;}
#t2g_2{left:55px;top:954px;word-spacing:10.9px;}
#t2h_2{left:55px;top:969px;word-spacing:8.8px;}
#t2i_2{left:373px;top:967px;}
#t2j_2{left:382px;top:967px;}
#t2k_2{left:388px;top:969px;word-spacing:13.3px;}
#t2l_2{left:55px;top:984px;word-spacing:-4.5px;}
#t2m_2{left:139px;top:983px;}
#t2n_2{left:148px;top:983px;}
#t2o_2{left:154px;top:984px;word-spacing:6.6px;}
#t2p_2{left:306px;top:983px;}
#t2q_2{left:315px;top:983px;}
#t2r_2{left:320px;top:984px;word-spacing:14px;}
#t2s_2{left:55px;top:999px;word-spacing:-4.6px;}
#t2t_2{left:121px;top:998px;}
#t2u_2{left:131px;top:998px;}
#t2v_2{left:140px;top:999px;}
#t2w_2{left:319px;top:998px;}
#t2x_2{left:328px;top:998px;}
#t2y_2{left:333px;top:999px;word-spacing:3.2px;}
#t2z_2{left:55px;top:1014px;word-spacing:26.9px;}
#t30_2{left:55px;top:1030px;word-spacing:15.1px;}
#t31_2{left:55px;top:1045px;word-spacing:5.4px;}
#t32_2{left:215px;top:1045px;}
#t33_2{left:229px;top:1045px;word-spacing:5.4px;}
#t34_2{left:55px;top:1060px;word-spacing:6.1px;}
#t35_2{left:55px;top:1075px;}
#t36_2{left:55px;top:1091px;word-spacing:0.6px;}
#t37_2{left:55px;top:1106px;word-spacing:-1.4px;}
#t38_2{left:188px;top:1104px;}
#t39_2{left:197px;top:1104px;}
#t3a_2{left:203px;top:1106px;}
#t3b_2{left:210px;top:1106px;}
#t3c_2{left:219px;top:1106px;}
#t3d_2{left:232px;top:1106px;}
#t3e_2{left:475px;top:602px;word-spacing:13.2px;}
#t3f_2{left:806px;top:601px;}
#t3g_2{left:816px;top:601px;}
#t3h_2{left:829px;top:602px;}
#t3i_2{left:461px;top:618px;word-spacing:16px;}
#t3j_2{left:684px;top:616px;}
#t3k_2{left:694px;top:616px;}
#t3l_2{left:710px;top:618px;word-spacing:29.7px;}
#t3m_2{left:461px;top:633px;}
#t3n_2{left:465px;top:633px;}
#t3o_2{left:474px;top:633px;}
#t3p_2{left:487px;top:633px;word-spacing:7.1px;}
#t3q_2{left:461px;top:648px;word-spacing:4.6px;}
#t3r_2{left:461px;top:663px;word-spacing:11.1px;}
#t3s_2{left:461px;top:678px;letter-spacing:-0.8px;word-spacing:-4.7px;}
#t3t_2{left:525px;top:677px;}
#t3u_2{left:535px;top:677px;}
#t3v_2{left:544px;top:678px;letter-spacing:-0.8px;word-spacing:2.4px;}
#t3w_2{left:798px;top:678px;}
#t3x_2{left:811px;top:678px;letter-spacing:-1px;}
#t3y_2{left:461px;top:694px;}
#t3z_2{left:467px;top:694px;}
#t40_2{left:480px;top:694px;word-spacing:0.7px;}
#t41_2{left:603px;top:692px;}
#t42_2{left:613px;top:692px;}
#t43_2{left:623px;top:694px;word-spacing:6px;}
#t44_2{left:461px;top:709px;word-spacing:3.1px;}
#t45_2{left:664px;top:709px;}
#t46_2{left:677px;top:709px;}
#t47_2{left:686px;top:709px;}
#t48_2{left:699px;top:709px;word-spacing:3.1px;}
#t49_2{left:461px;top:724px;word-spacing:1.3px;}
#t4a_2{left:461px;top:739px;word-spacing:18px;}
#t4b_2{left:696px;top:738px;}
#t4c_2{left:705px;top:738px;}
#t4d_2{left:710px;top:739px;word-spacing:29.3px;}
#t4e_2{left:461px;top:755px;letter-spacing:-1.2px;word-spacing:-5px;}
#t4f_2{left:524px;top:753px;}
#t4g_2{left:534px;top:753px;}
#t4h_2{left:539px;top:755px;letter-spacing:-1px;word-spacing:-0.7px;}
#t4i_2{left:691px;top:753px;}
#t4j_2{left:701px;top:753px;}
#t4k_2{left:709px;top:755px;letter-spacing:-1.4px;word-spacing:1.8px;}
#t4l_2{left:461px;top:770px;word-spacing:3.4px;}
#t4m_2{left:650px;top:768px;}
#t4n_2{left:660px;top:768px;}
#t4o_2{left:670px;top:770px;word-spacing:4.3px;}
#t4p_2{left:825px;top:768px;}
#t4q_2{left:835px;top:768px;}
#t4r_2{left:461px;top:785px;word-spacing:6.6px;}
#t4s_2{left:461px;top:800px;word-spacing:6.8px;}
#t4t_2{left:461px;top:815px;word-spacing:6.1px;}
#t4u_2{left:461px;top:831px;word-spacing:3.7px;}
#t4v_2{left:825px;top:829px;}
#t4w_2{left:835px;top:829px;}
#t4x_2{left:461px;top:846px;word-spacing:22.8px;}
#t4y_2{left:461px;top:861px;word-spacing:19.5px;}
#t4z_2{left:461px;top:876px;word-spacing:-4.7px;}
#t50_2{left:511px;top:875px;}
#t51_2{left:521px;top:875px;}
#t52_2{left:526px;top:876px;word-spacing:2.8px;}
#t53_2{left:693px;top:875px;}
#t54_2{left:703px;top:875px;}
#t55_2{left:713px;top:876px;word-spacing:5.7px;}
#t56_2{left:461px;top:892px;word-spacing:5.1px;}
#t57_2{left:669px;top:890px;}
#t58_2{left:678px;top:890px;}
#t59_2{left:689px;top:892px;word-spacing:8.9px;}
#t5a_2{left:461px;top:907px;word-spacing:0.8px;}
#t5b_2{left:667px;top:905px;}
#t5c_2{left:677px;top:905px;}
#t5d_2{left:687px;top:907px;word-spacing:4.4px;}
#t5e_2{left:461px;top:922px;word-spacing:1.6px;}
#t5f_2{left:461px;top:937px;word-spacing:7.7px;}
#t5g_2{left:461px;top:952px;word-spacing:-4.7px;}
#t5h_2{left:511px;top:951px;}
#t5i_2{left:521px;top:951px;}
#t5j_2{left:531px;top:952px;word-spacing:2.9px;}
#t5k_2{left:790px;top:951px;}
#t5l_2{left:800px;top:951px;}
#t5m_2{left:809px;top:952px;}
#t5n_2{left:461px;top:968px;}
#t5o_2{left:461px;top:983px;word-spacing:9.5px;}
#t5p_2{left:461px;top:998px;word-spacing:1.6px;}
#t5q_2{left:558px;top:997px;}
#t5r_2{left:568px;top:997px;}
#t5s_2{left:573px;top:998px;word-spacing:4.2px;}
#t5t_2{left:750px;top:997px;}
#t5u_2{left:759px;top:997px;}
#t5v_2{left:770px;top:998px;word-spacing:7.8px;}
#t5w_2{left:461px;top:1013px;word-spacing:2.5px;}
#t5x_2{left:689px;top:1012px;}
#t5y_2{left:698px;top:1012px;}
#t5z_2{left:708px;top:1013px;word-spacing:5.3px;}
#t60_2{left:461px;top:1029px;word-spacing:4.7px;}
#t61_2{left:475px;top:1044px;word-spacing:1.5px;}
#t62_2{left:461px;top:1059px;word-spacing:6.5px;}
#t63_2{left:461px;top:1074px;word-spacing:4.4px;}
#t64_2{left:461px;top:1089px;word-spacing:12px;}
#t65_2{left:461px;top:1105px;word-spacing:16.3px;}
#t66_2{left:467px;top:88px;word-spacing:4.5px;}
#t67_2{left:517px;top:89px;letter-spacing:-0.1px;word-spacing:3.9px;}
#t68_2{left:472px;top:112px;word-spacing:3.8px;}
#t69_2{left:472px;top:126px;word-spacing:-4.1px;}
#t6a_2{left:503px;top:125px;}
#t6b_2{left:511px;top:125px;}
#t6c_2{left:520px;top:126px;}
#t6d_2{left:523px;top:126px;}
#t6e_2{left:530px;top:126px;}
#t6f_2{left:741px;top:112px;word-spacing:4px;}
#t6g_2{left:472px;top:153px;word-spacing:3.7px;}
#t6h_2{left:624px;top:153px;}
#t6i_2{left:635px;top:153px;}
#t6j_2{left:484px;top:167px;word-spacing:3.7px;}
#t6k_2{left:750px;top:167px;word-spacing:4.1px;}
#t6l_2{left:484px;top:181px;word-spacing:3.7px;}
#t6m_2{left:750px;top:181px;word-spacing:4.1px;}
#t6n_2{left:484px;top:194px;word-spacing:3.7px;}
#t6o_2{left:750px;top:194px;word-spacing:4.1px;}
#t6p_2{left:472px;top:222px;word-spacing:4.2px;}
#t6q_2{left:547px;top:222px;}
#t6r_2{left:558px;top:222px;}
#t6s_2{left:484px;top:236px;word-spacing:3.7px;}
#t6t_2{left:750px;top:236px;word-spacing:4.1px;}
#t6u_2{left:484px;top:249px;}
#t6v_2{left:750px;top:249px;word-spacing:4.1px;}
#t6w_2{left:484px;top:263px;}
#t6x_2{left:750px;top:263px;word-spacing:4.1px;}
#t6y_2{left:484px;top:277px;letter-spacing:0.1px;word-spacing:3.9px;}
#t6z_2{left:750px;top:277px;word-spacing:4.1px;}
#t70_2{left:484px;top:290px;word-spacing:4.2px;}
#t71_2{left:750px;top:290px;word-spacing:4.1px;}
#t72_2{left:484px;top:304px;word-spacing:4px;}
#t73_2{left:750px;top:304px;word-spacing:4.1px;}
#t74_2{left:472px;top:331px;word-spacing:3.7px;}
#t75_2{left:568px;top:331px;}
#t76_2{left:579px;top:331px;}
#t77_2{left:484px;top:345px;letter-spacing:-0.1px;}
#t78_2{left:750px;top:345px;word-spacing:4.1px;}
#t79_2{left:484px;top:359px;}
#t7a_2{left:743px;top:359px;word-spacing:4px;}
#t7b_2{left:484px;top:373px;}
#t7c_2{left:556px;top:373px;}
#t7d_2{left:567px;top:373px;}
#t7e_2{left:750px;top:373px;word-spacing:4.1px;}
#t7f_2{left:472px;top:400px;word-spacing:4px;}
#t7g_2{left:735px;top:400px;word-spacing:3.9px;}
#t7h_2{left:472px;top:427px;word-spacing:3.7px;}
#t7i_2{left:472px;top:441px;word-spacing:3.7px;}
#t7j_2{left:735px;top:427px;word-spacing:3.9px;}
#t7k_2{left:472px;top:455px;word-spacing:3.7px;}
#t7l_2{left:472px;top:468px;word-spacing:3.8px;}
#t7m_2{left:735px;top:455px;word-spacing:3.9px;}
#t7n_2{left:472px;top:482px;word-spacing:-0.2px;}
#t7o_2{left:472px;top:496px;word-spacing:3.8px;}
#t7p_2{left:735px;top:482px;word-spacing:3.9px;}
#t7q_2{left:467px;top:519px;word-spacing:8.8px;}
#t7r_2{left:467px;top:533px;word-spacing:20.8px;}
#t7s_2{left:467px;top:547px;letter-spacing:-0.1px;word-spacing:4.2px;}
#t7t_2{left:461px;top:34px;word-spacing:3.9px;}
#t7u_2{left:461px;top:49px;word-spacing:4px;}
#t7v_2{left:536px;top:49px;word-spacing:3.9px;}
#t7w_2{left:858px;top:69px;}
#t7x_2{left:55px;top:1147px;}
#t7y_2{left:67px;top:1147px;word-spacing:3.7px;}
#t7z_2{left:534px;top:1147px;word-spacing:2.8px;}

.s6_2{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: JBCNGH-AdvOT65f8a23b-I2;
	color: rgb(35,31,32);
}

.s17_2{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: JBCNGG-AdvP4C4E742;
	color: rgb(35,31,32);
}

.s14_2{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: JBCNFE-AdvTT6780a46b2;
	color: rgb(35,31,32);
}

.s18_2{
	FONT-SIZE: 45.7px;
	FONT-FAMILY: JBCNFE-AdvTT6780a46b2;
	color: rgb(35,31,32);
}

.s5_2{
	FONT-SIZE: 32.5px;
	FONT-FAMILY: JBCNFF-AdvOT46dcae812;
	color: rgb(35,31,32);
}

.s19_2{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCPDD-AdvOT7d2ebc012;
	color: rgb(35,31,32);
}

.s4_2{
	FONT-SIZE: 32.5px;
	FONT-FAMILY: JBCNGG-AdvP4C4E742;
	color: rgb(35,31,32);
}

.s11_2{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNGK-AdvPi12;
	color: rgb(35,31,32);
}

.s12_2{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNGH-AdvOT65f8a23b-I2;
	color: rgb(35,31,32);
}

.s1_2{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNGI-AdvOT3b30f6db-B2;
	color: rgb(35,31,32);
}

.s7_2{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNFF-AdvOT46dcae812;
	color: rgb(35,31,32);
}

.s10_2{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNGG-AdvP4C4E742;
	color: rgb(35,31,32);
}

.s15_2{
	FONT-SIZE: 32.5px;
	FONT-FAMILY: JBCNFE-AdvTT6780a46b2;
	color: rgb(35,31,32);
}

.s13_2{
	FONT-SIZE: 51.8px;
	FONT-FAMILY: JBCOEH-AdvOT919a0533-B2;
	color: rgb(35,31,32);
}

.s20_2{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: JBCOAH-AdvTA422;
	color: rgb(35,31,32);
}

.s9_2{
	FONT-SIZE: 36.5px;
	FONT-FAMILY: JBCNFF-AdvOT46dcae812;
	color: rgb(35,31,32);
}

.s16_2{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: JBCOFH-AdvMyriad_I2;
	color: rgb(35,31,32);
}

.s8_2{
	FONT-SIZE: 36.5px;
	FONT-FAMILY: JBCNGG-AdvP4C4E742;
	color: rgb(35,31,32);
}

.s2_2{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: JBCNFF-AdvOT46dcae812;
	color: rgb(35,31,32);
}

.s3_2{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: JBCNGJ-AdvEls-ent42;
	color: rgb(35,31,32);
}

.v1_2{
	-webkit-transform: scale(0.281, 0.25);
	-ms-transform: scale(0.281, 0.25);
	-moz-transform: scale(0.281, 0.25);
	-o-transform: scale(0.281, 0.25);
}

#form2_1{	border-style:none;	z-index:2;	position: absolute;	left:177px;	top:333px;	width:11px;	height:14px;	text-align:left;	background: transparent;	font:normal 10px Arial, Helvetica, sans-serif;}
#form2_2{	border-style:none;	z-index:2;	position: absolute;	left:300px;	top:1047px;	width:44px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_3{	border-style:none;	z-index:2;	position: absolute;	left:717px;	top:649px;	width:44px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_4{	border-style:none;	z-index:2;	position: absolute;	left:356px;	top:697px;	width:44px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}

</style>
<style id="fonts2" type="text/css" >

@font-face {
	font-family: JBCOAH-AdvTA422;
	src: url("2/fonts/JBCOAH-AdvTA42.woff") format("woff");
}

@font-face {
	font-family: JBCNGG-AdvP4C4E742;
	src: url("2/fonts/JBCNGG-AdvP4C4E74.woff") format("woff");
}

@font-face {
	font-family: JBCNFF-AdvOT46dcae812;
	src: url("2/fonts/JBCNFF-AdvOT46dcae81.woff") format("woff");
}

@font-face {
	font-family: JBCOFH-AdvMyriad_I2;
	src: url("2/fonts/JBCOFH-AdvMyriad_I.woff") format("woff");
}

@font-face {
	font-family: JBCNGJ-AdvEls-ent42;
	src: url("2/fonts/JBCNGJ-AdvEls-ent4.woff") format("woff");
}

@font-face {
	font-family: JBCOEH-AdvOT919a0533-B2;
	src: url("2/fonts/JBCOEH-AdvOT919a0533-B.woff") format("woff");
}

@font-face {
	font-family: JBCNGK-AdvPi12;
	src: url("2/fonts/JBCNGK-AdvPi1.woff") format("woff");
}

@font-face {
	font-family: JBCNGI-AdvOT3b30f6db-B2;
	src: url("2/fonts/JBCNGI-AdvOT3b30f6db-B.woff") format("woff");
}

@font-face {
	font-family: JBCNGH-AdvOT65f8a23b-I2;
	src: url("2/fonts/JBCNGH-AdvOT65f8a23b-I.woff") format("woff");
}

@font-face {
	font-family: JBCNFE-AdvTT6780a46b2;
	src: url("2/fonts/JBCNFE-AdvTT6780a46b.woff") format("woff");
}

@font-face {
	font-family: JBCPDD-AdvOT7d2ebc012;
	src: url("2/fonts/JBCPDD-AdvOT7d2ebc01.woff") format("woff");
}

</style>
<div id="t1_2" class="t s1_2">MATERIALS AND METHODS</div>
<div id="t2_2" class="t s2_2">A retrospective review of all hypogonadal men with a history of CaP</div>
<div id="t3_2" class="t s2_2">treated with either brachytherapy or EBRT (collectively referred to as</div>
<div id="t4_2" class="t s2_2">‘radiation treatment’) who subsequently received TRT at Baylor College</div>
<div id="t5_2" class="t s2_2">of Medicine was performed after Institutional Review Board approval; 17</div>
<div id="t6_2" class="t s2_2">men were identiFed, 4 of whom were excluded owing to lack of available</div>
<div id="t7_2" class="t s2_2">prostate biopsy data or baseline PSA values. All men underwent radiation</div>
<div id="t8_2" class="t s2_2">treatment for CaP between 1994 and 2009 and TRT was initiated</div>
<div id="t9_2" class="t s2_2">between 2006 and 2010. The diagnosis of hypogonadism was based on</div>
<div id="ta_2" class="t s2_2">the presence of symptoms, including low libido, erectile dysfunction, low</div>
<div id="tb_2" class="t s2_2">energy, poor concentration, inadvertent weight gain and sleep distur-</div>
<div id="tc_2" class="t s2_2">bances, as well as serum T</div>
<div id="td_2" class="t s3_2">p</div>
<div id="te_2" class="t s2_2">300 ng dl</div>
<div id="tf_2" class="t v1_2 s4_2">±</div>
<div id="tg_2" class="t v1_2 s5_2">1</div>
<div id="th_2" class="t s2_2">. Initial TRT consisted of a trans-</div>
<div id="ti_2" class="t s2_2">dermal T formulation in 12 patients and subcutaneous T pellets in</div>
<div id="tj_2" class="t s2_2">1 patient. ±our patients were placed on androgen deprivation therapy</div>
<div id="tk_2" class="t s2_2">(ADT) prior to starting radiation treatment, one of whom was diagnosed</div>
<div id="tl_2" class="t s2_2">with high-grade disease. Men were also risk-stratiFed using the National</div>
<div id="tm_2" class="t s2_2">Comprehensive Cancer Network (NCCN) guidelines and 4, 7 and 2 patients</div>
<div id="tn_2" class="t s2_2">were found to be at very low or low, intermediate, or high risk for CaP</div>
<div id="to_2" class="t s2_2">recurrence, respectively.</div>
<div id="tp_2" class="t v1_2 s5_2">19</div>
<div id="tq_2" class="t s2_2">Baseline serum T, free T (±T), hemoglobin (Hgb), hematocrit (Hct),</div>
<div id="tr_2" class="t s2_2">estrogen (E), sex hormone-binding globulin (SHBG) and PSA levels were</div>
<div id="ts_2" class="t s2_2">determined after completion of EBRT or placement of brachytherapy</div>
<div id="tt_2" class="t s2_2">seeds, but before initiation of TRT. Subsequent hormonal evaluation was</div>
<div id="tu_2" class="t s2_2">performed approximately every 3 months after TRT initiation. PSA velocity</div>
<div id="tv_2" class="t s2_2">(PSAV) was calculated using linear regression of three or more serum PSA</div>
<div id="tw_2" class="t s2_2">values obtained over at least a 12-month period. Of note, PSAV was not</div>
<div id="tx_2" class="t s2_2">determined for one patient, as only two PSA values were available and</div>
<div id="ty_2" class="t s2_2">these were within 5 months of each other. The majority of serum hormone</div>
<div id="tz_2" class="t s2_2">evaluations were performed by the Laboratory for Male Reproductive</div>
<div id="t10_2" class="t s2_2">Research and Testing at Baylor College of Medicine on a single Beckman</div>
<div id="t11_2" class="t s2_2">Coulter Access2 assay system (Beckman Coulter, Brea, CA, USA), with a</div>
<div id="t12_2" class="t s2_2">minority of samples analyzed by outside laboratories. Subjective improve-</div>
<div id="t13_2" class="t s2_2">ment in libido, erections and energy was assessed using direct questioning</div>
<div id="t14_2" class="t s2_2">of patients prior to initiation of TRT and during follow-up.</div>
<div id="t15_2" class="t s2_2">Data were analyzed using Microsoft OfFce Excel (Microsoft, Redmond,</div>
<div id="t16_2" class="t s2_2">WA, USA) and SPSS (IBM Corporation, Somers, NY, USA). Statistical com-</div>
<div id="t17_2" class="t s2_2">parisons between baseline and follow-up values were performed using</div>
<div id="t18_2" class="t s2_2">the Wilcoxon rank-sum test, with a</div>
<div id="t19_2" class="t s6_2">P</div>
<div id="t1a_2" class="t s2_2">-value</div>
<div id="t1b_2" class="t s3_2">p</div>
<div id="t1c_2" class="t s2_2">0.05 considered statistically</div>
<div id="t1d_2" class="t s2_2">signiFcant.</div>
<div id="t1e_2" class="t s1_2">RESULTS</div>
<div id="t1f_2" class="t s7_2">Thirteen hypogonadal patients with a history of CaP were treated</div>
<div id="t1g_2" class="t s7_2">with TRT after completion of radiation treatment (Table 1). The</div>
<div id="t1h_2" class="t s7_2">median time to initiation of TRT after radiation treatment was 13.5</div>
<div id="t1i_2" class="t s7_2">months, and the time from initiation of radiation treatment to last</div>
<div id="t1j_2" class="t s7_2">follow-up PSA was 45.6 months. The median age at TRT initiation</div>
<div id="t1k_2" class="t s7_2">was 68.0 years. Prostate biopsy results evidenced four patients</div>
<div id="t1l_2" class="t s7_2">with Gleason (Gl) 6, 7 with Gl 7 and 2 with Gl 8 disease, with no</div>
<div id="t1m_2" class="t s7_2">men having evidence of locally advanced CaP. Using the NCCN</div>
<div id="t1n_2" class="t s7_2">guidelines to risk stratify our cohort, we found 4, 7 and 2 patients</div>
<div id="t1o_2" class="t s7_2">to be at very low or low, intermediate, or high risk for CaP</div>
<div id="t1p_2" class="t s7_2">recurrence, respectively. Of the 13 patients in the cohort, 3 were</div>
<div id="t1q_2" class="t s7_2">treated with brachytherapy and 10 with EBRT. ±our patients</div>
<div id="t1r_2" class="t s7_2">received ADT in addition to radiation treatment for PSA levels of</div>
<div id="t1s_2" class="t s7_2">1.9, 14, 15 and 18 ng ml</div>
<div id="t1t_2" class="t v1_2 s8_2">±</div>
<div id="t1u_2" class="t v1_2 s9_2">1</div>
<div id="t1v_2" class="t s7_2">and Gl 4</div>
<div id="t1w_2" class="t s10_2">þ</div>
<div id="t1x_2" class="t s7_2">3</div>
<div id="t1y_2" class="t s10_2">¼</div>
<div id="t1z_2" class="t s7_2">7, 4</div>
<div id="t20_2" class="t s10_2">þ</div>
<div id="t21_2" class="t s7_2">3</div>
<div id="t22_2" class="t s10_2">¼</div>
<div id="t23_2" class="t s7_2">7, 3</div>
<div id="t24_2" class="t s10_2">þ</div>
<div id="t25_2" class="t s7_2">4</div>
<div id="t26_2" class="t s10_2">¼</div>
<div id="t27_2" class="t s7_2">7</div>
<div id="t28_2" class="t s7_2">and 4</div>
<div id="t29_2" class="t s10_2">þ</div>
<div id="t2a_2" class="t s7_2">4</div>
<div id="t2b_2" class="t s10_2">¼</div>
<div id="t2c_2" class="t s7_2">8 disease, respectively. Three patients were started on</div>
<div id="t2d_2" class="t s7_2">TRT prior to being diagnosed with CaP and TRT was restarted after</div>
<div id="t2e_2" class="t s7_2">CaP treatment.</div>
<div id="t2f_2" class="t s7_2">The median follow-up period after TRT initiation was 29.7</div>
<div id="t2g_2" class="t s7_2">months (range 2.3–67.3 months). Baseline median (interquartile</div>
<div id="t2h_2" class="t s7_2">range) serum values were: T 178.0 (88.0–263.5) ng dl</div>
<div id="t2i_2" class="t v1_2 s8_2">±</div>
<div id="t2j_2" class="t v1_2 s9_2">1</div>
<div id="t2k_2" class="t s7_2">, ±T 5.1</div>
<div id="t2l_2" class="t s7_2">(3.6–5.8) pg ml</div>
<div id="t2m_2" class="t v1_2 s8_2">±</div>
<div id="t2n_2" class="t v1_2 s9_2">1</div>
<div id="t2o_2" class="t s7_2">, E 18.0 (11.0–35.0) pg ml</div>
<div id="t2p_2" class="t v1_2 s8_2">±</div>
<div id="t2q_2" class="t v1_2 s9_2">1</div>
<div id="t2r_2" class="t s7_2">, SHBG 31.5 (19.3–</div>
<div id="t2s_2" class="t s7_2">36.5) nmol l</div>
<div id="t2t_2" class="t v1_2 s8_2">±</div>
<div id="t2u_2" class="t v1_2 s9_2">1</div>
<div id="t2v_2" class="t s7_2">and PSA 0.30 (0.06–0.95) ng ml</div>
<div id="t2w_2" class="t v1_2 s8_2">±</div>
<div id="t2x_2" class="t v1_2 s9_2">1</div>
<div id="t2y_2" class="t s7_2">. Median serum T</div>
<div id="t2z_2" class="t s7_2">was signiFcantly higher after TRT initiation compared with</div>
<div id="t30_2" class="t s7_2">baseline throughout the duration of follow-up, except for the</div>
<div id="t31_2" class="t s7_2">time periods of 18–24 and</div>
<div id="t32_2" class="t s11_2">4</div>
<div id="t33_2" class="t s7_2">30 months (Table 2). No signiFcant</div>
<div id="t34_2" class="t s7_2">increases from baseline ±T or E were observed during follow-up.</div>
<div id="t35_2" class="t s7_2">There was an overall increase in the mean SHBG during the course</div>
<div id="t36_2" class="t s7_2">of treatment with signiFcance reached at 18–24 months follow-up</div>
<div id="t37_2" class="t s7_2">(38.5 (34.3–56.3) nmol l</div>
<div id="t38_2" class="t v1_2 s8_2">±</div>
<div id="t39_2" class="t v1_2 s9_2">1</div>
<div id="t3a_2" class="t s7_2">,</div>
<div id="t3b_2" class="t s12_2">P</div>
<div id="t3c_2" class="t s10_2">¼</div>
<div id="t3d_2" class="t s7_2">0.042).</div>
<div id="t3e_2" class="t s7_2">Median PSA in the cohort was 0.30 (42.8–49.0) ng ml</div>
<div id="t3f_2" class="t v1_2 s8_2">±</div>
<div id="t3g_2" class="t v1_2 s9_2">1</div>
<div id="t3h_2" class="t s7_2">at</div>
<div id="t3i_2" class="t s7_2">baseline and 0.66 (0.16–1.35) ng ml</div>
<div id="t3j_2" class="t v1_2 s8_2">±</div>
<div id="t3k_2" class="t v1_2 s9_2">1</div>
<div id="t3l_2" class="t s7_2">at median follow-up</div>
<div id="t3m_2" class="t s7_2">(</div>
<div id="t3n_2" class="t s12_2">P</div>
<div id="t3o_2" class="t s10_2">¼</div>
<div id="t3p_2" class="t s7_2">0.345). No signiFcant changes in PSA were observed during</div>
<div id="t3q_2" class="t s7_2">the follow-up period of up to 67.3 months (Table 2). The median</div>
<div id="t3r_2" class="t s7_2">difference between baseline and PSA at median follow-up was</div>
<div id="t3s_2" class="t s7_2">0.055 ng ml</div>
<div id="t3t_2" class="t v1_2 s8_2">±</div>
<div id="t3u_2" class="t v1_2 s9_2">1</div>
<div id="t3v_2" class="t s7_2">and the median PSAV within the cohort was</div>
<div id="t3w_2" class="t s10_2">±</div>
<div id="t3x_2" class="t s7_2">0.004</div>
<div id="t3y_2" class="t s7_2">(</div>
<div id="t3z_2" class="t s10_2">±</div>
<div id="t40_2" class="t s7_2">0.080 to 0.010) ng ml</div>
<div id="t41_2" class="t v1_2 s8_2">±</div>
<div id="t42_2" class="t v1_2 s9_2">1</div>
<div id="t43_2" class="t s7_2">per year. Biochemical recurrence was</div>
<div id="t44_2" class="t s7_2">suspected in one patient with Gl 4</div>
<div id="t45_2" class="t s10_2">þ</div>
<div id="t46_2" class="t s7_2">4</div>
<div id="t47_2" class="t s10_2">¼</div>
<div id="t48_2" class="t s7_2">8 disease who had been</div>
<div id="t49_2" class="t s7_2">treated with brachytherapy as well as ADT. This patient had a pre-</div>
<div id="t4a_2" class="t s7_2">radiation treatment PSA of 18 ng ml</div>
<div id="t4b_2" class="t v1_2 s8_2">±</div>
<div id="t4c_2" class="t v1_2 s9_2">1</div>
<div id="t4d_2" class="t s7_2">, a pre-TRT PSA of</div>
<div id="t4e_2" class="t s7_2">0.009 ng ml</div>
<div id="t4f_2" class="t v1_2 s8_2">±</div>
<div id="t4g_2" class="t v1_2 s9_2">1</div>
<div id="t4h_2" class="t s7_2">, with a nadir of 0.002 ng ml</div>
<div id="t4i_2" class="t v1_2 s8_2">±</div>
<div id="t4j_2" class="t v1_2 s9_2">1</div>
<div id="t4k_2" class="t s7_2">after starting TRT, which</div>
<div id="t4l_2" class="t s7_2">subsequently rose to 1.82 ng ml</div>
<div id="t4m_2" class="t v1_2 s8_2">±</div>
<div id="t4n_2" class="t v1_2 s9_2">1</div>
<div id="t4o_2" class="t s7_2">with a PSAV of 0.93 ng ml</div>
<div id="t4p_2" class="t v1_2 s8_2">±</div>
<div id="t4q_2" class="t v1_2 s9_2">1</div>
<div id="t4r_2" class="t s7_2">per year, prompting cessation of TRT and workup for CaP recur-</div>
<div id="t4s_2" class="t s7_2">rence. Repeat prostate biopsy, computed tomography and bone</div>
<div id="t4t_2" class="t s7_2">scans showed no evidence of cancer, at which point the patient</div>
<div id="t4u_2" class="t s7_2">resumed TRT. His PSA has since remained stable at 1.31 ng ml</div>
<div id="t4v_2" class="t v1_2 s8_2">±</div>
<div id="t4w_2" class="t v1_2 s9_2">1</div>
<div id="t4x_2" class="t s7_2">on TRT. The second patient who received ADT in addition</div>
<div id="t4y_2" class="t s7_2">to radiation treatment had a pre-radiation treatment PSA of</div>
<div id="t4z_2" class="t s7_2">15 ng ml</div>
<div id="t50_2" class="t v1_2 s8_2">±</div>
<div id="t51_2" class="t v1_2 s9_2">1</div>
<div id="t52_2" class="t s7_2">, a baseline PSA of 0.4 ng ml</div>
<div id="t53_2" class="t v1_2 s8_2">±</div>
<div id="t54_2" class="t v1_2 s9_2">1</div>
<div id="t55_2" class="t s7_2">prior to TRT initiation,</div>
<div id="t56_2" class="t s7_2">and a maximum PSA of 1.29 ng ml</div>
<div id="t57_2" class="t v1_2 s8_2">±</div>
<div id="t58_2" class="t v1_2 s9_2">1</div>
<div id="t59_2" class="t s7_2">while on TRT, which sub-</div>
<div id="t5a_2" class="t s7_2">sequently decreased to 0.629 ng ml</div>
<div id="t5b_2" class="t v1_2 s8_2">±</div>
<div id="t5c_2" class="t v1_2 s9_2">1</div>
<div id="t5d_2" class="t s7_2">during treatment. TRT was</div>
<div id="t5e_2" class="t s7_2">not stopped at any point during this patient’s follow-up. The third</div>
<div id="t5f_2" class="t s7_2">patient who received ADT had a pre-radiation treatment PSA of</div>
<div id="t5g_2" class="t s7_2">14 ng ml</div>
<div id="t5h_2" class="t v1_2 s8_2">±</div>
<div id="t5i_2" class="t v1_2 s9_2">1</div>
<div id="t5j_2" class="t s7_2">while on TRT, a maximum PSA of 0.30 ng ml</div>
<div id="t5k_2" class="t v1_2 s8_2">±</div>
<div id="t5l_2" class="t v1_2 s9_2">1</div>
<div id="t5m_2" class="t s7_2">while</div>
<div id="t5n_2" class="t s7_2">on TRT, with stable PSA and no evidence of recurrence. ±inally, the</div>
<div id="t5o_2" class="t s7_2">fourth patient who received ADT had a pre-radiation treatment</div>
<div id="t5p_2" class="t s7_2">PSA of 1.9 ng ml</div>
<div id="t5q_2" class="t v1_2 s8_2">±</div>
<div id="t5r_2" class="t v1_2 s9_2">1</div>
<div id="t5s_2" class="t s7_2">, a baseline PSA of 0.09 ng ml</div>
<div id="t5t_2" class="t v1_2 s8_2">±</div>
<div id="t5u_2" class="t v1_2 s9_2">1</div>
<div id="t5v_2" class="t s7_2">prior to TRT</div>
<div id="t5w_2" class="t s7_2">initiation, a maximum PSA of 0.1 ng ml</div>
<div id="t5x_2" class="t v1_2 s8_2">±</div>
<div id="t5y_2" class="t v1_2 s9_2">1</div>
<div id="t5z_2" class="t s7_2">during treatment, with</div>
<div id="t60_2" class="t s7_2">transient cessation of TRT due to supraphysiological T levels.</div>
<div id="t61_2" class="t s7_2">A side effect of exogenous T administration is the development</div>
<div id="t62_2" class="t s7_2">of erythrocytosis. In our cohort, only three patients had baseline</div>
<div id="t63_2" class="t s7_2">Hgb and Hct values available and, as a result, we were unable to</div>
<div id="t64_2" class="t s7_2">make direct comparisons between baseline and follow-up Hgb</div>
<div id="t65_2" class="t s7_2">and Hct. However, the maximum Hgb and Hct in any single</div>
<div id="t66_2" class="t s13_2">Table 1.</div>
<div id="t67_2" class="t s14_2">Patient Demographics</div>
<div id="t68_2" class="t s14_2">Pre-radiation treatment PSA, median (IQR),</div>
<div id="t69_2" class="t s14_2">ng ml</div>
<div id="t6a_2" class="t v1_2 s4_2">±</div>
<div id="t6b_2" class="t v1_2 s15_2">1</div>
<div id="t6c_2" class="t s14_2">(</div>
<div id="t6d_2" class="t s16_2">n</div>
<div id="t6e_2" class="t s14_2">)</div>
<div id="t6f_2" class="t s14_2">5.8 (3.0–14.0), (9)</div>
<div id="t6g_2" class="t s16_2">Prostate biopsy Gleason sum (</div>
<div id="t6h_2" class="t s14_2">n</div>
<div id="t6i_2" class="t s16_2">(%))</div>
<div id="t6j_2" class="t s14_2">Gleason 6</div>
<div id="t6k_2" class="t s14_2">4 (31%)</div>
<div id="t6l_2" class="t s14_2">Gleason 7</div>
<div id="t6m_2" class="t s14_2">7 (54%)</div>
<div id="t6n_2" class="t s14_2">Gleason 8</div>
<div id="t6o_2" class="t s14_2">2 (15%)</div>
<div id="t6p_2" class="t s16_2">Comorbidities (</div>
<div id="t6q_2" class="t s14_2">n</div>
<div id="t6r_2" class="t s16_2">(%))</div>
<div id="t6s_2" class="t s14_2">Diabetes mellitus</div>
<div id="t6t_2" class="t s14_2">2 (15%)</div>
<div id="t6u_2" class="t s14_2">Hypertension</div>
<div id="t6v_2" class="t s14_2">5 (38%)</div>
<div id="t6w_2" class="t s14_2">Hyperlipidemia</div>
<div id="t6x_2" class="t s14_2">3 (23%)</div>
<div id="t6y_2" class="t s14_2">Coronary artery disease</div>
<div id="t6z_2" class="t s14_2">3 (23%)</div>
<div id="t70_2" class="t s14_2">Smoking (previous or current)</div>
<div id="t71_2" class="t s14_2">5 (38%)</div>
<div id="t72_2" class="t s14_2">Post-radiotherapy erectile dysfunction</div>
<div id="t73_2" class="t s14_2">9 (69%)</div>
<div id="t74_2" class="t s16_2">Cancer Treatment (</div>
<div id="t75_2" class="t s14_2">n</div>
<div id="t76_2" class="t s16_2">(%))</div>
<div id="t77_2" class="t s14_2">Brachytherapy</div>
<div id="t78_2" class="t s14_2">3 (23%)</div>
<div id="t79_2" class="t s14_2">EBRT</div>
<div id="t7a_2" class="t s14_2">10 (77%)</div>
<div id="t7b_2" class="t s14_2">Radiotherapy</div>
<div id="t7c_2" class="t s17_2">þ</div>
<div id="t7d_2" class="t s14_2">ADT</div>
<div id="t7e_2" class="t s14_2">4 (31%)</div>
<div id="t7f_2" class="t s14_2">Age at TRT initiation (years), median (IQR)</div>
<div id="t7g_2" class="t s14_2">68.0 (62.0–77.0)</div>
<div id="t7h_2" class="t s14_2">Months between XRT completion and TRT</div>
<div id="t7i_2" class="t s14_2">initiation, median (range)</div>
<div id="t7j_2" class="t s14_2">13.5 (2.6–170.9)</div>
<div id="t7k_2" class="t s14_2">Months between XRT completion and last</div>
<div id="t7l_2" class="t s14_2">follow-up PSA, median (range)</div>
<div id="t7m_2" class="t s14_2">45.6 (11.7–219.8)</div>
<div id="t7n_2" class="t s14_2">Months between TRT initiation and last follow-</div>
<div id="t7o_2" class="t s14_2">up PSA, median (range)</div>
<div id="t7p_2" class="t s14_2">29.7 (2.3–67.3)</div>
<div id="t7q_2" class="t s18_2">Abbreviations: ADT, androgen deprivation therapy; EBRT, external beam</div>
<div id="t7r_2" class="t s18_2">radiotherapy; IQR, interquartile range; PSA, prostate-speciFc antigen;</div>
<div id="t7s_2" class="t s18_2">TRT, testosterone replacement therapy; XRT, radiation therapy.</div>
<div id="t7t_2" class="t s2_2">Testosterone replacement after radiation treatment for prostate cancer</div>
<div id="t7u_2" class="t s2_2">AW Pastuszak</div>
<div id="t7v_2" class="t s6_2">et al</div>
<div id="t7w_2" class="t s19_2">25</div>
<div id="t7x_2" class="t s20_2">&amp;</div>
<div id="t7y_2" class="t s2_2">2013 Macmillan Publishers Limited</div>
<div id="t7z_2" class="t s2_2">International Journal of Impotence Research (2013), 24 – 28</div>

<form>
<input type="button"  tabindex="1"  id="form2_1" name="2 0 R"  pdfFieldName="2 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="3"  id="form2_2" name="4 0 R"  pdfFieldName="4 0 R" onclick="window.location.href='3.html';" style="cursor:pointer;"  title="Page 3" />
<input type="button"  tabindex="4"  id="form2_3" name="5 0 R"  pdfFieldName="5 0 R" onclick="window.location.href='3.html';" style="cursor:pointer;"  title="Page 3" />
<input type="button"  tabindex="2"  id="form2_4" name="3 0 R"  pdfFieldName="3 0 R" onclick="window.location.href='2.html';" style="cursor:pointer;"  title="Page 2" />

</form>
<div id="pg2Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg2"><object width="909" height="1212" data="2/2.svg" type="image/svg+xml" id="pdf2" style="width:909px; height:1212px; background-color:white; -moz-transform:scale(1); z-index: 0;"></object></div>
<!--[if lt IE 9]><script type="text/javascript">
var divCount = 288;
for (var i = 1; i < divCount; i++) {
    var div = document.getElementById("t" + i.toString(36) + "_2");
    if (div !== null) {
        div.style.top = (div.offsetTop * 4) + "px";
        div.style.left = (div.offsetLeft * 4) + "px";
        div.style.zoom = "25%";
    }
}
</script><![endif]-->

</div>
